In a new dissection of data from the italic language subset of the large clinical study REST (Rotavirus Efficacy and Safety Trial), the five-type rotavirus vaccine RotaTeq demonstrated 100%a clinical efficacy against severe rotavirus disease for the first rotavirus season after vaccinationb. The efficacy remained high through two rotavirus seasons of follow up, preventing 98%c of severe rotavirus cases. [click link for full article]

More: - From the site